PEAR PEAR THERAPEUTICS INC

Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference

(Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. ET.

Pear will be available for one-on-one meetings during the conference. Investors interested in meeting with Pear at the conference should contact their Evercore representative.

A live audio webcast of the presentation can be accessed by clicking and will be made available in the Investors section of Pear’s website at . A replay of the webcast will be available on Pear’s website for up to 30 days following the live presentation.

About Pear Therapeutics

Pear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas., including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at .

EN
21/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PEAR THERAPEUTICS INC

 PRESS RELEASE

Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Th...

BOSTON--(BUSINESS WIRE)-- Pear Therapeutics, Inc. (Nasdaq: PEAR) (“the Company”), a company focused on developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that the Company and its wholly owned subsidiary, Pear Therapeutics (US), Inc. (collectively, the “Debtors”) each voluntarily filed for protection under chapter 11 (“Chapter 11”) of the U.S. Bankruptcy Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) and they intend to pursue a sale of the business or a...

 PRESS RELEASE

Pear Therapeutics Announces Process Exploring Strategic Alternatives

BOSTON--(BUSINESS WIRE)-- (Nasdaq: PEAR) (“the Company”), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value. The Company has engaged MTS Health Partners, L.P. to act as the Company’s exclusive financial advisor to assist in evaluating potential alternatives. MTS Health Partners is a leading boutique investment bank that provides strategic and financial advice to the healthcare industry. As part of its process, Pea...

 PRESS RELEASE

Pear Therapeutics to Participate in 43rd Annual Cowen Healthcare Confe...

BOSTON--(BUSINESS WIRE)-- (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the 43rd Annual Cowen Healthcare Conference being held March 6-8, 2023 in Boston. Corey McCann, M.D., Ph.D., President and CEO, will represent the Company in an analyst-led fireside chat on Monday, March 6 at 9:10 a.m. Eastern Time. A live audio webcast can be accessed by clicking and will be made available in the Investors section of Pear’s website at . A replay of the webcast will be...

 PRESS RELEASE

Pear Therapeutics to Participate in the 2023 BTIG MedTech, Digital Hea...

BOSTON--(BUSINESS WIRE)-- (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the Company will participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference, which takes place February 14 - 16, 2023 in Snowbird, UT. Pear management will participate virtually in 1x1 meetings at the conference. BTIG hosted events are intended for prospective and existing BTIG clients only. To request a meeting with Pear management, please contact your BTIG representative to express i...

 PRESS RELEASE

Pear Therapeutics and BrightView Health Expand Pilot Program to Provid...

BOSTON--(BUSINESS WIRE)-- (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today the expansion of its collaboration with , an addiction treatment provider that offers evidence-based, outpatient addiction treatment programs. This initiative is designed to provide eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD) access to reSET® and reSET-O®. BrightView, an innovative and patient-focused leader in SUD and OUD treatment, began piloting Pear’s products in its ce...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch